|
Vol. 10.30 – 4 August, 2021
|
|
|
|
|
|
Scientists found STAT5B to be specifically activated in HSCs and leukemic stem cells, where it induced many genes associated with quiescence and self-renewal, including the surface marker CD9. [Blood]
|
|
|
|
|
PUBLICATIONSRanked by the impact factor of the journal
|
|
|
|
|
The authors described a novel multi-kinase inhibitor, 108600, that suppressed growth, colony and mammosphere forming capacity of breast cancer stem cell-like cells and induced G2M arrest and apoptosis of triple-negative breast cancer cells. [Nature Communications]
|
|
|
|
|
Circular RNA stabilizing HOXC10 (cis-HOX) was robustly expressed in colorectal tumor-initiating cells (TICs). cis-HOX knockout decreased colorectal TIC numbers and impaired the self-renewal, tumorigenesis, and metastatic capacities of TICs, whereas cis-HOX overexpression drove colorectal TIC self-renewal and metastasis.
[Cell Reports]
|
|
|
|
|
Macrophages co-cultured with breast cancer cells showed a significant increase in CCL2 expression and promoted β-Catenin-induced breast cancer stem cells (BCSCs) properties, whereas depletion of CCL2 by adding neutralizing antibodies suppressed BSCSs properties.
[Oncogene]
|
|
|
|
|
The authors examined the expression of RNF141 in 64 pairs of colorectal cancer and adjacent normal tissues by real-time PCR, Western blot, and immunohistochemical analysis.
[Oncogene]
|
|
|
|
|
To identify drivers of sarcoma cancer stem-like cells, investigators compared gene expression using RNA sequencing between HT1080 fibrosarcoma and SK-LMS-1 leiomyosarcoma spheroids compared with the parent populations.
[Cell Death & Disease]
|
|
|
|
|
Researchers showed that sublethal doxorubicin treatment led to increased migration and invasion in otherwise non-invasive MCF7 breast cancer cells.
[Breast Cancer Research]
|
|
|
|
|
An ovarian cancer cell line, PEO4, was initially reprogrammed into induced pluripotent stem cells using the classical four factors OCT4, SOX2, KLF4 and MYC using lentivirus transduction.
[International Journal of Biochemistry & Cell Biology]
|
|
|
|
|
Different concentrations of doxorubicin (DOX), graphene oxide, and graphene oxide plus doxorubicin (GO-DOX) were subjected to MCF7 and BT474 human breast cancer cells at specified intervals. [Applied Biochemistry and Biotechnology]
|
|
|
|
|
|
Investigators discuss the role of hypoxia facilitating senescence bypass during malignant transformation and acquisition of stemness properties, which all contribute to tumor development and cancer disease aggressiveness. [Journal of Experimental & Clinical Cancer Research]
|
|
|
|
|
|
Calidi Biotherapeutics, Inc., announced that it has executed a license agreement with Northwestern University for the exclusive commercialization rights to the IND and data generated from Northwestern’s Phase 1 clinical trial treating brain tumor patients with an engineered oncolytic adenovirus delivered by neural stem cells.
[Calidi Biotherapeutics, Inc.]
|
|
|
|
|
Ambrx announced the first patient has been dosed in a Phase I, multicenter, open-label, dose-escalation, and dose expansion study to evaluate the safety, pharmacokinetics, and anti-tumor activity of ARX517 in subjects with prostate specific membrane antigen (PSMA) expressing tumors found in prostate, pancreatic, lung and ovarian cancers.
[Ambrx (BusinessWire, Inc.)]
|
|
|
|
|
|
October 21 – 22, 2021 Virtual
|
|
|
|
|
|
|
Pfizer, Inc. – Boulder, Colorado; New York City, New York; San Francisco, California, United States
|
|
|
|
|
The University of British Columbia – Vancouver, British Columbia, Canada
|
|
|
|
|
Westwood Bioscience, Inc. – Los Angeles, California, United States
|
|
|
|
|
University of Gothenburg – Gothenburg, Sweden
|
|
|
|
|
CRUK Manchester Institute – Manchester, England, United Kingdom
|
|
|
|
|